phase 1 clinical trial | sciencenewsnet.in

Breaking News

Insurance challenges limit psychologists’ capacity to address ongoing mental health needs

$10.8 million grant supports cutting-edge leukemia research

Healthy eating habits to carry you through the holidays

Dr. Edward J. Feser Named 34th President of Saint Louis University

ما هي تنبؤاتك الصحية؟ خبير يشرح التفسير العلمي وراء التوجيهات الشخصية المتعلقة بالعافية

NYU Tandon researchers create microchips capable of detecting and diagnosing diseases

Governor Hochul Celebrates the Opening Of New York’s First Cell and Gene Therapy Hub at Roswell Park Comprehensive Cancer Center in Buffalo

Across southeastern US, weedy rice steals herbicide resistance from crop rice

Threat of abrupt mortality events keeps endangered monkey population at risk, despite decades of growth

Controller with Integrated Machine Learning Tweaks Fusion Plasmas in Real Time

17 Dec, 2024

Kazia Therapeutics Announces Presentation of EVT801 Clinical Data at 15th Biennial Ovarian Cancer Research Symposium

September 23, 2024 sarah JonasAnnouncement

Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, is pleased to announce the presentation of data highlighting promising clinical activity of EVT801 in high grade serous (HGS) Ovarian Cancer at the 15th Biennial Ovarian Cancer Research Symposium, co-presented by American Association of Cancer Research (AACR) and the Rivkin Center for Ovarian Cancer Research on Saturday, September 21, 2024 in Seattle Washington.